← Vivus (INVA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vivus (INVA)
Pharmaceutical Preparations · market cap $1.5B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
6
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Vivus (INVA) is a pharmaceutical company with a $1.6B market cap, a diversified pipeline spanning obesity, erectile dysfunction, Alzheimer's disease, diabetes, sexual dysfunction, and lymphoma. The company is profitable and cash-generative, reporting $411M in revenue and $271M in net income in 2025, with $603M in cash and net cash of $345M on the balance sheet.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-03-31 (est.)Phase 2 · VI-0609imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| VI-0521 | Phase 3 | Obesity |
| avanafil | Phase 3 | Erectile Dysfunction |
| VI-1121 | Phase 2 | Alzheimer's Disease |
| Phentermine/Topiramate | Phase 2 | Diabetes |
| Topical alprostadil (PGE-1) | Phase 2 | Sexual Dysfunction, Physiological |
| VI-0609 | Phase 2 | Lymphoma |
Price & technical context
3-month
-5.9%
6-month
-10.7%
12-month
+13.0%
52-wk range
$16.67–$24.24
vs 50-day MA
-2.2%
vs 200-day MA
-5.6%
Realized vol
27.5%
Max drawdown
-23.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INVA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.